{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:35:44Z","timestamp":1782952544909,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014565","name":"Bausch Health Companies Inc Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clinthera.2025.03.005","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T07:09:02Z","timestamp":1744960142000},"page":"445-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Canadian Real-World Study of Fixed-DOSE combination of Halobetasol Propionate 0.01%\/Tazarotene 0.045% Lotion for the Treatment of Moderate-to-Severe Plaque Psoriasis"],"prefix":"10.1016","volume":"47","author":[{"given":"R","family":"Vender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Zeinab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Legault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HC-H","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.03.005_bib0001","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Canadian Fam Phys"},{"issue":"2","key":"10.1016\/j.clinthera.2025.03.005_bib0002","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD\u2013NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2025.03.005_bib0003","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1468-3083.2012.04522.x","article-title":"Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities","volume":"26","author":"Castela","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2025.03.005_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/561018","article-title":"Mechanisms of action of topical corticosteroids in psoriasis","volume":"2012","author":"Uva","year":"2012","journal-title":"Int J Endocrinol"},{"issue":"4","key":"10.1016\/j.clinthera.2025.03.005_bib0005","first-page":"957-962","article-title":"Topical psoriasis therapy","volume":"59","author":"Federman","year":"1999","journal-title":"Am Fam Physician"},{"issue":"2 Pt 3","key":"10.1016\/j.clinthera.2025.03.005_bib0006","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0190-9622(97)80396-9","article-title":"Molecular mechanisms of tazarotene action in psoriasis","volume":"37","author":"Duvic","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.clinthera.2025.03.005_bib0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archderm.134.1.57","article-title":"The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis","volume":"134","author":"Krueger","year":"1998","journal-title":"Arch Dermatol"},{"issue":"5 Pt 1","key":"10.1016\/j.clinthera.2025.03.005_bib0008","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0190-9622(98)70594-8","article-title":"Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis","volume":"38","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.clinthera.2025.03.005_bib0009","first-page":"1280","article-title":"Tazarotene Revisited: safety and efficacy in plaque psoriasis and its emerging role in treatment strategy","volume":"17","author":"Tanghetti","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.clinthera.2025.03.005_bib0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1067\/mjd.2003.103","article-title":"Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks","volume":"48","author":"Weinstein","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.clinthera.2025.03.005_bib0011","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1517\/14656566.4.12.2347","article-title":"The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis","volume":"4","author":"Koo","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.clinthera.2025.03.005_bib0012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/120347540200600201","article-title":"A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis","volume":"6","author":"Green","year":"2002","journal-title":"J Cutan Med Surg"},{"issue":"4 Pt 1","key":"10.1016\/j.clinthera.2025.03.005_bib0013","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0190-9622(98)70008-8","article-title":"Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.clinthera.2025.03.005_bib0014","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaad.2018.03.040","article-title":"Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials","volume":"79","author":"Gold","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.clinthera.2025.03.005_bib0015","first-page":"855","article-title":"Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies","volume":"17","author":"Sugarman","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2025.03.005_bib0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2011.04060.x","article-title":"Maximizing patient adherence for optimal outcomes in psoriasis","volume":"25","author":"Bewley","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.clinthera.2025.03.005_bib0017","first-page":"46","article-title":"Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis","volume":"94","author":"Eastman","year":"2014","journal-title":"Cutis"},{"issue":"11","key":"10.1016\/j.clinthera.2025.03.005_bib0018","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/jdv.14515","article-title":"Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study","volume":"31","author":"Hong","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.clinthera.2025.03.005_bib0019","first-page":"111","article-title":"Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies","volume":"103","author":"Sugarman","year":"2019","journal-title":"Cutis"},{"issue":"8","key":"10.1016\/j.clinthera.2025.03.005_bib0020","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/jdv.15450","article-title":"Itch: an under-recognized problem in psoriasis","volume":"33","author":"Elewski","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2025.03.005_bib0021","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1477-7525-7-62","article-title":"The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups","volume":"7","author":"Globe","year":"2009","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"10.1016\/j.clinthera.2025.03.005_bib0022","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2133.2000.03829.x","article-title":"The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis","volume":"143","author":"Yosipovitch","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2025.03.005_bib0023","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jdin.2022.06.013","article-title":"Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: analysis of the single-arm, open-label, multicenter, prospective ProLOGUE study","volume":"8","author":"Miyagi","year":"2022","journal-title":"JAAD Int"},{"issue":"5","key":"10.1016\/j.clinthera.2025.03.005_bib0024","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.clinthera.2025.03.005_bib0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2340\/00015555-2642","article-title":"Tailoring the cut-off values of the visual analogue scale and numeric rating scale in itch assessment","volume":"97","author":"Reich","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.clinthera.2025.03.005_bib0026","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2340\/00015555-1972","article-title":"Comparative cut-off value setting of pruritus intensity in visual analogue scale and verbal rating scale","volume":"95","author":"Kido-Nakahara","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"10.1016\/j.clinthera.2025.03.005_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101539","article-title":"Does the vehicle matter? Real-world evidence on adherence to topical treatment in psoriasis","volume":"13","author":"Teixeira","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.clinthera.2025.03.005_bib0028","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s13555-016-0119-4","article-title":"Patient preferences for topical psoriasis treatments are diverse and difficult to predict","volume":"6","author":"Iversen","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2025.03.005_bib0029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jdv.12445","article-title":"Non-adherence and measures to improve adherence in the topical treatment of psoriasis","volume":"28","author":"Zschocke","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:01:32Z","timestamp":1762246892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0149291825000815"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.03.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Canadian Real-World Study of Fixed-DOSE combination of Halobetasol Propionate 0.01%\/Tazarotene 0.045% Lotion for the Treatment of Moderate-to-Severe Plaque Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}